Business Model Breakdown
How Clearpoint Neuro Inc Makes Money
CLPT
Market Cap
$350M
Annual Revenue
$37M
Profit Margin
-69.1%
The Short Version
Clearpoint Neuro develops and commercializes an advanced MRI-guided neuro-navigation platform used primarily for precise delivery of gene and cell therapies into the brain and other difficult-to-reach areas of the central nervous system. They generate revenue by selling their sophisticated hardware systems, providing consumable components that are required for each procedure, and offering technical support and related services to neurosurgeons, hospitals, academic research institutions, and pharmaceutical/biotech companies conducting clinical trials. Their core value proposition lies in enabling highly accurate, minimally invasive, and repeatable delivery of novel neurotherapies.
Where the Revenue Comes From
Hardware System Sales (MRI-guided platforms)
Consumables (disposable surgical components for each procedure)
Services (technical support, maintenance, training, and clinical trial support)
Who buys: Neurosurgeons, hospitals, academic research institutions, and pharmaceutical/biotech companies (primarily for clinical trial support and future commercial applications).
Why It Works (Competitive Advantages)
- ✔Proprietary MRI-guided neuro-navigation platform
- ✔Strong intellectual property portfolio
- ✔Established strategic partnerships with leading pharmaceutical/biotech companies
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Efficient Scale)
What Our Analysis Says
DVR Score as of April 19, 2026
Clearpoint Neuro (CLPT) maintains its strong investment case as a critical enabling technology for the rapidly evolving neuro gene and cell therapy sector. The company's proprietary MRI-guided navigation platform, robust IP, and strategic partnerships provide a significant and expanding competitive moat, positioning it for future market leadership. Despite current unprofitability (TTM net income -$22.22M, negative FCF), which is typical for early-stage high-growth medtech, the existing cash reserves (> $41M post-debt) suggest a manageable burn rate and sufficient runway. No material changes in company fundamentals, market conditions, or strategic announcements have occurred since the last analysis to warrant a significant score adjustment, thus maintaining consistency with the prior high score. The fundamental thesis of enabling a massive therapeutic market with a scalable model remains strong, supporting a high potential for 10x growth within 3-5 years.